NHS Dudley Health Economy Medicines Formulary
Home > 1 Gastro-intestinal system > 1.5 Chronic bowel disorders > 1.5.3 Drugs affecting the immune response > Vedolizumab for treating moderately to severely active ulcerative colitis - NICE TAG TA342

Vedolizumab for treating moderately to severely active ulcerative colitis - NICE TAG TA342

1.1 Vedolizumab is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults only if the company provides vedolizumab with the discount agreed in the patient access scheme.

1.2 Vedolizumab should be given until it stops working or surgery is needed. At 12 months after the start of treatment, people should be reassessed to see whether treatment should continue. Treatment should only continue if there is clear evidence of ongoing clinical benefit. For people in complete remission at 12 months, consider stopping vedolizumab, resuming treatment if there is a relapse. People who continue vedolizumab should be reassessed at least every 12 months to see whether continued treatment is justified.

 

http://www.nice.org.uk/guidance/ta342

Site by Devopa
© Copyright 2021 NHS. All rights reserved.